Myeloproliferative neoplasms (MPNs) offer a unique opportunity to investigate whether specific mutations lead to distinct epigenetic changes, as they feature unique driver mutations in Janus kinase 2 (JAK2), particularly at the amino acid position 617 (valine to phenylalanine, V617F), calreticulin (CALR), and myeloproliferative leukemia protein (MPL) [1]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.